Apicore US LLC

Alembic Pharmaceuticals Limited

Rk Pharma Solutions LLC

Ananda Babu Thirunavakarasu

Ravishanker Kovi

Jayaraman Rao Kannapan

Veerabhadra Rao Bobbili

Gaurav Yadav

Mahender Rao Siripragada

Sanjay F Thakor

Shivnath Sahebrao Patil

Piyush D Fadadu

Hemant Mande

Pinky Parikh

Dinesh Panchasara

Ilesh Patel

Bhavesh Prajapati

Ankit Shah

Piyush B Thumar

Processes are disclosed for making vortioxetine and pharmaceutically acceptable salts thereof. A propylene glycol solvate of vortioxetine hydrobromide is disclosed. A novel crystalline form of vortioxetine hydrobromide propylene glycol solvate, designated form AC1, is disclosed along with a method for making same. Form AC1 may be characterized by an x-ray powder diffraction pattern with peaks at about 19.64, 22.85, 25.51, 29.57, 30.18&#xb1;0.2 degrees 2-theta.

Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts

Novel polymorphs of rucaparib camsylate include Form alpha having XRPD peaks at diffraction angles (2&#x3b8;) of 6.14&#xb1;0.2, 12.41&#xb1;0.2, 15.34&#xb1;0.2, 15.95&#xb1;0.2, 16.36&#xb1;0.2, 16.51&#xb1;0.2 and 19.67&#xb1;0.2, Form beta having XRPD peaks at diffraction angles (2&#x3b8;) of 6.86&#xb1;0.2, 9.58&#xb1;0.2, 12.75&#xb1;0.2, 14.56&#xb1;0.2, 15.05&#xb1;0.2, 20.76&#xb1;0.2 and 22.45&#xb1;0.2, and Form gamma having XRPD peaks at diffraction angles (2&#x3b8;) of 9.5&#xb1;0.2, 12.73&#xb1;0.2, 14.77&#xb1;0.2, 15.16&#xb1;0.2, 20.62&#xb1;0.2, 22.33&#xb1;0.2, 22.63&#xb1;0.2 and 27.29&#xb1;0.2. Methods are disclosed for the preparation of such polymorphic forms and pharmaceutical compositions containing such polymorphic forms. A method is disclosed for preparing a highly pure Form B of rucaparib camsylate. Pharmaceutical compositions containing highly pure Form B prepared by the method are disclosed.

Polymorphs of rucaparib camsylate and methods of making same

The present invention provides an improved process for the preparation of Apremilast using novel intermediates. The present invention also relates to the novel crystalline polymorphic form of Apremilast.

Process and novel polymorphic form of Apremilast

Processes are provided for the preparation of a stable polymorphic form C of regadenoson, the process involving steps of a) obtaining a solution of regadenoson in benzyl alcohol solvent, b) maintaining the reaction mixture of step a) to about 10&#xb0; C. to about 90&#xb0; C., and c) isolating the stable polymorphic form C of regadenoson. Polymorphic form C may be characterized by an x-ray powder diffraction pattern with peaks at about 6.1, 10.2, 10.6, 19.0 and 25.4.&#xb1;0.2 degrees 2-theta.

Polymorph of regadenoson and process for preparation thereof

Novel crystalline ponatinib hydrochloride forms designated Form alpha and Form beta are disclosed. Form alpha is characterized by data selected from an XRPD pattern with peaks at about 6.5, 9.0, 12.25, 14.4, 16.70, 19.6, 22.2, 24.5, 28.2&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or a combination thereof. Form beta is characterized by data selected from an XRPD pattern with peaks at about 10.7, 15.2, 15.8, 16.4 23.1, 25.0, 27.8&#xb1;0.2 degrees 2-theta; an XRPD pattern substantially as depicted in FIG.; and/or combinations thereof. Processes for making Form alpha and Form beta are disclosed.

Polymorphs of ponatinib hydrochloride

Growing community of inventors

Gujarat, India

Ananda Babu Thirunavakarasu